In:
Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-12-6)
Abstract:
HTR2A is previously identified as a susceptibility gene for rheumatoid arthritis (RA). In this study, we performed the association analysis between DNA methylation of HTR2A with RA within peripheral blood samples. Methods We enrolled peripheral blood samples from 235 patients with RA, 30 osteoarthritis (OA) patients, and 30 healthy controls. The DNA methylation levels of about 218 bp from chr13: 46898190 to chr13: 46897973 (GRCh38/hg38) around HTR2A cg15692052 from patients were analyzed by targeted methylation sequencing. Results We measured methylation status for 7 CpGs in the promoter region of HTR2A and obseved overall methylation status are signficantly increased in RA compared with normal inviduals (FDR= 9.05 x 10 -5 ). The average cg15692052 methylation levels (methylation score) showed a positive correlation with CRP (r=0.15, P =0.023). Compared with the OA group or HC group, the proportion of haplotypes CCCCCCC ( FDR =0.02 and 2.81 x 10 -6 ) is signficantly increased while TTTTTCC ( FDR =0.01) and TTTTTTT( FDR =6.92 x 10 -3 ) are significantly decreased in RA. We find methylation haplotypes combining with RF and CCP could signficantly enhance the performance of the diagnosing RA and its comorbidities (hypertension, interstitial lung disease, and osteoporosis), especially in interstitial lung disease. Conclusions In our study, we found signficant hypermethylation of promoter region of HTR2A which indicates the potential clinical diagnostic role in rheumatoid arthritis.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2022.1054451
DOI:
10.3389/fimmu.2022.1054451.s001
DOI:
10.3389/fimmu.2022.1054451.s002
DOI:
10.3389/fimmu.2022.1054451.s003
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8